Sareum Restarts Phase 2-Enabling Toxicology Programme for Lead Autoimmune Drug SDC-1801

Sareum Holdings ( (GB:SAR) ) has shared an announcement.

Sareum Holdings has restarted its Phase 2-enabling toxicology programme for SDC-1801, a selective TYK2/JAK1 inhibitor in development for autoimmune diseases with an initial focus on psoriasis, after appointing a leading global contract research organisation to run the long-term studies. Supported by preliminary pharmacokinetic work and funded from existing cash resources, the toxicology dosing phase is expected to finish by mid-2026, with the full Phase 2-enabling package targeted for completion by year-end, advancing the asset toward Phase 2 trials and reinforcing its potential as a once-daily, best-in-class oral therapy.

The most recent analyst rating on (GB:SAR) stock is a Hold with a £18.50 price target. To see the full list of analyst forecasts on Sareum Holdings stock, see the GB:SAR Stock Forecast page.

Spark’s Take on GB:SAR Stock

According to Spark, TipRanks’ AI Analyst, GB:SAR is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue, recurring losses, and ongoing cash burn requiring external funding). Technicals provide a partial offset with strong momentum above major moving averages, but overbought signals add risk. Valuation remains constrained due to negative earnings and no dividend support.

To see Spark’s full report on GB:SAR stock, click here.

More about Sareum Holdings

Sareum Holdings is a Cambridge, UK-based biotechnology company listed on AIM, focused on developing next-generation small-molecule kinase inhibitors for autoimmune diseases and cancer. Its lead asset, SDC-1801, is a dual TYK2/JAK1 inhibitor initially targeting psoriasis, alongside SDC-1802 for certain blood cancers and a new preclinical TYK2/JAK1 programme for neuroinflammatory diseases, as well as the recently in-licensed CHK1 cancer candidate SRA737.

Average Trading Volume: 217,153

Technical Sentiment Signal: Sell

Current Market Cap: £25.54M

See more data about SAR stock on TipRanks’ Stock Analysis page.